Research Article

Erythromycin resistance in Group A Beta-hemolytic streptococci

Volume: 4 Number: 4 October 22, 2022
EN

Erythromycin resistance in Group A Beta-hemolytic streptococci

Abstract

Aim: Streptococcus pyogenes (Group A Beta-hemolytic streptococci, GABHS) is one of the important bacterial pathogens in clinical microbiology. It often causes upper respiratory tract infections such as tonsillitis, pharyngitis, and laryngitis. It also leads to complications such as acute rheumatic fever and post-streptococcal glomerulonephritis. Early diagnosis and treatment of these bacterial infections will prevent suppurative and non-suppurative complications, the transmission of infection to other people, and chronic carriage. Today, the treatment of streptococcal infections relies entirely on chemotherapy. Beta hemolytic group A streptococci and generally other beta-hemolytic streptococci in groups B (GBBHS), C, and G are generally sensitive to many chemotherapeutics, especially Penicillin and Erythromycin. In patients with penicillin allergy, erythromycin, amoxicillin-clavulanate, or oral cephalosporins are used instead of penicillin. However, it has recently been understood that there are strains resistant to Erythromycin in GABHS and are increasing. In this study, the situation in our region of Erythromycin resistance, which is used as an alternative for people allergic to Penicillin in the treatment of streptococcal infections, was investigated. Material and Method: In our study, throat swab samples were taken from 150 pharyngitis patients and 94 GABHS were obtained by applying the Bacitracin-SXT test with the culture method, and antibiotic susceptibility tests were performed on these 94 GABHS by Kirby-Bauer agar disc diffusion method. Result: GABHS was found susceptible to Bacitracin and resistant to SXT. GBBHS is resistant to Bacitracin and SXT. other beta-hemolytic streptococci were resistant to Bacitracin and susceptible to SXT. Conclusion: In this study, Erythromycin’s resistance was found to be 19.1%. it is observed that Erythromycin resistance has increased over the years when compared to previous studies. Erythromycin should not be used empirically in treatment. An antibiotic susceptibility test should be performed and the antibiotic should be selected according to the results of the antibiogram test.

Keywords

Thanks

I would like to thank my late teacher Dr. Süheyla Öztürk for his support in my education and thesis work.

References

  1. Bisno AL, Mandel GL, Douglas RG, Bennett JE. Classification Of Streptococci In (ed) : Principles and Practise of Infectious Diseaes, vol 2 New York, Churchill Livingstone 1990: 1518-28.
  2. Facklam RR. Serologic identification of streptococci: How useful is serologic grouping? Clin Microbiol Newsletter 1985; 7: 91-4.
  3. Hardie SM. Genus Streptococcus Rosenbah 1884 in Hat JG, Sneath PHA (ed) Bergey’s Manual of Systematic Bacteriology, vol 2 Baltimore, Williams & Willins 1984: 1043-71.
  4. Bilgehan H. “Streptococcacene”, Klinik Mikrobiyoloji, Özel Bakteriyolaji ve Bakteri Enfeksiyonları, 1.Baskı, İzmir Barış Yayınları. 1990: 210-3.
  5. Baron EJ, Finegad SM. Bailey and Scott’s Diagnostic Microbiology 8th ed. St. Louis, The CU Mospy Co 1990: 332-52.
  6. Hedges JR. Sore Throat, to culture or not to culture. Ann Emerg Med 1986; 15: 312-6.
  7. Peters G, Smith A. Group A streptococcal infections of the skin and pharynx. N Engl J Med 1977: 297-311.
  8. Jawetz E, Melnick JL, Adelburg EA. Rewiew of Medical Microbiology 7th ed. California, Appleton and Lange1987: 223-37.

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Research Article

Publication Date

October 22, 2022

Submission Date

August 24, 2022

Acceptance Date

September 29, 2022

Published in Issue

Year 2022 Volume: 4 Number: 4

APA
Balcı, P. (2022). Erythromycin resistance in Group A Beta-hemolytic streptococci. Anatolian Current Medical Journal, 4(4), 421-425. https://doi.org/10.38053/acmj.1166370
AMA
1.Balcı P. Erythromycin resistance in Group A Beta-hemolytic streptococci. Anatolian Curr Med J / ACMJ / acmj. 2022;4(4):421-425. doi:10.38053/acmj.1166370
Chicago
Balcı, Pervin. 2022. “Erythromycin Resistance in Group A Beta-Hemolytic Streptococci”. Anatolian Current Medical Journal 4 (4): 421-25. https://doi.org/10.38053/acmj.1166370.
EndNote
Balcı P (October 1, 2022) Erythromycin resistance in Group A Beta-hemolytic streptococci. Anatolian Current Medical Journal 4 4 421–425.
IEEE
[1]P. Balcı, “Erythromycin resistance in Group A Beta-hemolytic streptococci”, Anatolian Curr Med J / ACMJ / acmj, vol. 4, no. 4, pp. 421–425, Oct. 2022, doi: 10.38053/acmj.1166370.
ISNAD
Balcı, Pervin. “Erythromycin Resistance in Group A Beta-Hemolytic Streptococci”. Anatolian Current Medical Journal 4/4 (October 1, 2022): 421-425. https://doi.org/10.38053/acmj.1166370.
JAMA
1.Balcı P. Erythromycin resistance in Group A Beta-hemolytic streptococci. Anatolian Curr Med J / ACMJ / acmj. 2022;4:421–425.
MLA
Balcı, Pervin. “Erythromycin Resistance in Group A Beta-Hemolytic Streptococci”. Anatolian Current Medical Journal, vol. 4, no. 4, Oct. 2022, pp. 421-5, doi:10.38053/acmj.1166370.
Vancouver
1.Pervin Balcı. Erythromycin resistance in Group A Beta-hemolytic streptococci. Anatolian Curr Med J / ACMJ / acmj. 2022 Oct. 1;4(4):421-5. doi:10.38053/acmj.1166370

 

TR DİZİN ULAKBİM and International Indexes (1b)
 

Interuniversity Board (UAK) Equivalency:  Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS]

Note: Our journal is not WOS indexed and therefore is not classified as Q.

You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/3449/file/4924/show

 

Journal Indexes and Platforms: 

TR Dizin ULAKBİM, Google Scholar, Crossref, Worldcat (OCLC), DRJI, EuroPub, OpenAIRE, Turkiye Citation Index, Turk Medline, ROAD, ICI World of Journal's, Index Copernicus, ASOS Index, General Impact Factor, Scilit.


 

The indexes of the journal's are;


 

download?token=eyJhdXRoX3JvbGVzIjpbXSwiZW5kcG9pbnQiOiJqb3VybmFsIiwib3JpZ2luYWxuYW1lIjoiVHJfSW5kZXhfbG9nby5wbmciLCJwYXRoIjoiMDFiOS82MmZhLzA3MzMvNjlkZjNlNTdhMmI4ZjkuODYxMzMxMjQucG5nIiwiZXhwIjoxNzc2MjQxNzY3LCJub25jZSI6ImQyMTQ4MjdiNTg1ZjVmMGQwYzAzZTMxNzMwM2QwMThmIn0.RmnGvwR536HdIoKpGO-ApytZ5aRPRT_BFXE2EpGSIqc

asos-index.png
 
f9ab67f.png
 
WorldCat_Logo_H_Color.png
 

 

18596download?token=eyJhdXRoX3JvbGVzIjpbXSwiZW5kcG9pbnQiOiJqb3VybmFsIiwib3JpZ2luYWxuYW1lIjoiT3BlbkFpcmUuanBnIiwicGF0aCI6IjUyMWYvZjljYy8wMDk3LzY5ZGYzZDNiYmVkZGU0LjQzNDM2OTU3LmpwZyIsImV4cCI6MTc3NjI0MTQ4NCwibm9uY2UiOiIwYjgxZDE2NzRiNzhjMWQyOGVmMDM1OTA1MzI5NjdjZiJ9.xeFppR1ubA4i-dHG-u07ht9bQNogFheXQjLyEaP9GgAimages?q=tbn:ANd9GcQgDnBwx0yUPRKuetgIurtELxYERFv20CPAUcPe4jYrrJiwXzac8rGXlzd57gl8iikb1Tk&usqp=CAU

 

84039476_619085835534619_7808805634291269632_n.jpg

 

 

 

The platforms of the journal's are;
 

COPE.jpg
 
images?q=tbn:ANd9GcTbq2FM8NTdXECzlOUCeKQ1dvrISFL-LhxhC7zy1ZQeJk-GGKSx2XkWQvrsHxcfhtfHWxM&usqp=CAUicmje_1_orig.png
 
 
ncbi.png
 
ORCID_logo.pngimages?q=tbn:ANd9GcQlwX77nfpy3Bu9mpMBZa0miWT2sRt2zjAPJKg2V69ODTrjZM1nT1BbhWzTVPsTNKJMZzQ&usqp=CAU
 

 

images?q=tbn:ANd9GcTaWSousoprPWGwE-qxwxGH2y0ByZ_zdLMN-Oq93MsZpBVFOTfxi9uXV7tdr39qvyE-U0I&usqp=CAU
 


 


 

 


 


The indexes/platforms of the journal are;
 

TR Dizin Ulakbim, Crossref (DOI), Google Scholar, EuroPub, Directory of Research Journal İndexing (DRJI), Worldcat (OCLC), OpenAIRE, ASOS Index, ROAD, Turkiye Citation Index, ICI World of Journal's, Index Copernicus, Turk Medline, General Impact Factor, Scilit 
 


Journal articles are evaluated as "Double-Blind Peer Review"

 

All articles published in this journal are licensed under a Creative Commons Attribution 4.0 International License (CC BY NC ND)